Evidence map›Paper›PMID 33656910›Full record

SynthesisJCO global oncology2021

Impact of Strategies for Mitigating Delays and Disruptions in Cancer Care Due to COVID-19: Systematic Review.

Rafael Leite Pacheco, Ana Luiza Cabrera Martimbianco, Felipe Roitberg, Andre Ilbawi, Rachel Riera

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in JCO global oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Rafael Leite PachecoCentro Universitário São Camilo (CUSC), São Paulo, Brazil.ORCID 0000-0001-7487-8471
Ana Luiza Cabrera MartimbiancoCentro Universitário São Camilo (CUSC), São Paulo, Brazil.
Felipe RoitbergInstituto do Câncer do Estado de São Paulo/HCFMUSP, World Health Organization (WHO), São Paulo, Brazil.
Andre IlbawiDepartment of Noncommunicable Diseases, World Health Organization (WHO) Headquarters, Geneva, Switzerland.ORCID 0000-0002-4751-6595
Rachel RieraCentre of Health Technology Assessment, Hospital Sírio-Libanês, São Paulo, Brazil.ORCID 0000-0002-9522-1871
Centro Universitário São Camilo · BREuropean Society for Medical Oncology · CHHospital Sírio-Libanês · BRUniversidade Metropolitana de Santos · BRWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

purposeDelays and disruptions in health systems because of the COVID-19 pandemic were identified by a previous systematic review from our group. For improving the knowledge about the pandemic consequences for cancer care, this article aims to identify the effects of mitigation strategies developed to reduce the impact of such delays and disruptions.

methodsSystematic review with a comprehensive search including formal databases, cancer and COVID-19 data sources, gray literature, and manual search. We considered clinical trials, observational longitudinal studies, cross-sectional studies, before-and-after studies, case series, and case studies. The selection, data extraction, and methodological assessment were performed by two independent reviewers. The methodological quality of the included studies was assessed by specific tools. The mitigation strategies identified were described in detail and their effects were summarized narratively.

resultsOf 6,692 references reviewed, 28 were deemed eligible, and 9 studies with low to moderate methodological quality were included. Five multiple strategies and four single strategies were reported, and the possible effects of mitigating delays and disruptions in cancer care because of COVID-19 are inconsistent. The only comparative study reported a 48.7% reduction observed in the number of outpatient visits to the hospital accompanied by a small reduction in imaging and an improvement in radiation treatments after the implementation of a multiple organizational strategy.

conclusionThe findings emphasize the infrequency of measuring and reporting mitigation strategies that specifically address patients' outcomes and thus a scarcity of high-quality evidence to inform program development. This review reinforces the need of adopting standardized measurement methods to monitor the impact of the mitigation strategies proposed to reduce the effects of delays and disruptions in cancer health care because of COVID-19.

Indexed as

Cancer Care FacilitiesHealthcare DisparitiesHealth Status DisparitiesCOVID-19Cross-Sectional StudiesDecision MakingHumansMedical OncologyModels, OrganizationalNeoplasmsOutcome Assessment, Health CarePandemicsTime-to-Treatment

Identifiers

PMID33656910
PMCPMC8081509
OpenAlexW3134380527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.